<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:37:57Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6600834" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6600834</identifier>
        <datestamp>2019-07-16</datestamp>
        <setSpec>annalsats</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="letter">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Ann Am Thorac Soc</journal-id>
              <journal-id journal-id-type="iso-abbrev">Ann Am Thorac Soc</journal-id>
              <journal-id journal-id-type="publisher-id">AnnalsATS</journal-id>
              <journal-title-group>
                <journal-title>Annals of the American Thoracic Society</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2329-6933</issn>
              <issn pub-type="epub">2325-6621</issn>
              <publisher>
                <publisher-name>American Thoracic Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6600834</article-id>
              <article-id pub-id-type="pmcid">PMC6600834</article-id>
              <article-id pub-id-type="pmc-uid">6600834</article-id>
              <article-id pub-id-type="pmid">30950636</article-id>
              <article-id pub-id-type="publisher-manuscript">201810-720RL</article-id>
              <article-id pub-id-type="doi">10.1513/AnnalsATS.201810-720RL</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Letters</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maher</surname>
                    <given-names>Toby M.</given-names>
                  </name>
                  <degrees>M.B.B.S., M.Sc., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lancaster</surname>
                    <given-names>Lisa H.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jouneau</surname>
                    <given-names>Stéphane</given-names>
                  </name>
                  <degrees>M.D., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morrison</surname>
                    <given-names>Lake</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5258-0228</contrib-id>
                  <name>
                    <surname>Lederer</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <degrees>M.D., M.S.</degrees>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fn2">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Molina-Molina</surname>
                    <given-names>Maria</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bendstrup</surname>
                    <given-names>Elisabeth</given-names>
                  </name>
                  <degrees>M.D., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kirchgaessler</surname>
                    <given-names>Klaus-Uwe</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gilberg</surname>
                    <given-names>Frank</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Axmann</surname>
                    <given-names>Judit</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Petzinger</surname>
                    <given-names>Ute</given-names>
                  </name>
                  <degrees>M.S.</degrees>
                  <xref ref-type="aff" rid="aff12">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Noble</surname>
                    <given-names>Paul W.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Royal Brompton Hospital<break/>London, United Kingdom</aff>
                <aff id="aff2"><label><sup>2</sup></label>Imperial College London<break/>London, United Kingdom</aff>
                <aff id="aff3"><label><sup>3</sup></label>Vanderbilt University Medical Center<break/>Nashville, Tennessee</aff>
                <aff id="aff4"><label><sup>4</sup></label>Pontchaillou University Hospital<break/>Rennes, France</aff>
                <aff id="aff5"><label><sup>5</sup></label>Rennes 1 University<break/>Rennes, France</aff>
                <aff id="aff6"><label><sup>6</sup></label>Duke University Medical Center<break/>Durham, North Carolina</aff>
                <aff id="aff7"><label><sup>7</sup></label>Columbia University Medical Center<break/>New York, New York</aff>
                <aff id="aff8"><label><sup>8</sup></label>Institut d’Investigació Biomèdica de Bellvitge<break/>Barcelona, Spain</aff>
                <aff id="aff9"><label><sup>9</sup></label>Centro de Investigación Biomédica en Red Enfermedades Respiratorias<break/>Madrid, Spain</aff>
                <aff id="aff10"><label><sup>10</sup></label>Aarhus University Hospital<break/>Aarhus, Denmark</aff>
                <aff id="aff11"><label><sup>11</sup></label>F. Hoffmann-La Roche, Ltd.<break/>Basel, Switzerland</aff>
                <aff id="aff12"><label><sup>12</sup></label>Accovion GmbH<break/>Eschborn, Germany<break/>and</aff>
                <aff id="aff13"><label><sup>13</sup></label>Cedars-Sinai Medical Center<break/>Los Angeles, California</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>*</label>Corresponding author (e-mail: <email xlink:href="t.maher@imperial.ac.uk">t.maher@imperial.ac.uk</email>).</corresp>
                <fn id="fn2">
                  <label>
                    <sup>‡</sup>
                  </label>
                  <p>D.J.L. is Editor-in-Chief of <italic>AnnalsATS</italic>. His participation complies with ATS requirements for recusal from review and decisions for authored works.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub-ppub">
                <month>7</month>
                <year>2019</year>
                <!--string-date: July 2019-->
              </pub-date>
              <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2019</year>
                <!--string-date: July 2019-->
              </pub-date>
              <pub-date pub-type="pmc-release">
                <month>7</month>
                <year>2019</year>
                <!--string-date: July 2019-->
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub-ppub"/>. -->
              <volume>16</volume>
              <issue>7</issue>
              <fpage>927</fpage>
              <lpage>930</lpage>
              <permissions>
                <copyright-statement>Copyright © 2019 by the American Thoracic Society</copyright-statement>
                <copyright-year>2019</copyright-year>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
                  <license-p>This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>). For commercial usage and reprints please contact Diane Gern (<email xlink:href="dgern@thoracic.org">dgern@thoracic.org</email>).</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="AnnalsATS.201810-720RL.pdf"/>
              <counts>
                <fig-count count="3"/>
                <table-count count="0"/>
                <page-count count="4"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p content-type="flushleft"><italic>To the Editor</italic>:</p>
            <p content-type="flushleft">Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, fatal, fibrosing lung disease (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>). Pirfenidone and nintedanib are oral antifibrotics with demonstrated efficacy in reducing lung function decline in individuals with IPF, independent of baseline lung function (<xref rid="bib3" ref-type="bibr">3</xref>–<xref rid="bib7" ref-type="bibr">7</xref>). Intervention with an antifibrotic as early as possible in the disease course might be the most appropriate strategy to preserve lung capacity (<xref rid="bib5" ref-type="bibr">5</xref>). However, many physicians are reluctant to initiate antifibrotics at diagnosis, and delay treatment until disease progression is observed (<xref rid="bib8" ref-type="bibr">8</xref>). Furthermore, certain countries do not reimburse antifibrotic treatment for individuals with preserved lung function (% predicted forced vital capacity [FVC] &gt; 80%) (<xref rid="bib8" ref-type="bibr">8</xref>). These <italic>post hoc</italic> analyses aimed to assess: <italic>1</italic>) FVC decline during long-term pirfenidone treatment in RECAP in individuals with IPF categorized by baseline % predicted FVC; and <italic>2</italic>) the impact of deferring pirfenidone treatment on annual FVC decline in individuals with IPF during CAPACITY (<xref rid="bib3" ref-type="bibr">3</xref>) and RECAP (<xref rid="bib9" ref-type="bibr">9</xref>).</p>
            <sec disp-level="2">
              <title>Methods</title>
              <p content-type="flushleft">RECAP (NCT00662038) was an open-label extension study, including individuals who had completed the double-blind, placebo-controlled trials of pirfenidone in individuals with IPF (ASCEND [Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis] [NCT01366209]; CAPACITY [Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes] [NCT00287716/NCT00287729]); the methods and primary outcomes of RECAP have been described previously (<xref rid="bib9" ref-type="bibr">9</xref>). Individuals who previously received pirfenidone or placebo treatment for 72–120 weeks in CAPACITY and received 2,403 mg/d pirfenidone during RECAP were included in the analyses. Individuals from ASCEND were not included due to lack of FVC follow-up data.</p>
              <p>Association of baseline FVC (at entry into RECAP) with rate of FVC decline during RECAP (first aim) was assessed over 180 weeks using change from baseline in % predicted FVC, categorized by baseline % predicted FVC (&lt;50%, ≥50% to &lt;60%, ≥60% to &lt;70%, ≥70% to &lt;80%, ≥80% to &lt;90%, and ≥90%).</p>
              <p>Association of timing of pirfenidone initiation with annual FVC decline (ml/yr) during CAPACITY and RECAP (second aim) was assessed over 220 weeks by categorizing individuals who completed CAPACITY and enrolled in RECAP by CAPACITY treatment group (2,403 mg/d pirfenidone or placebo; the 1,197 mg/d pirfenidone group was not included). Annual FVC decline was calculated for Weeks 0–120 (CAPACITY), Weeks 72–120 (the transition period), and Week 120 onward (RECAP), as described in <xref ref-type="fig" rid="fig1">Figure 1</xref>. This analysis was also stratified based on CAPACITY study of origin (004 or 006).</p>
              <fig id="fig1" orientation="portrait" position="float">
                <label>Figure 1.</label>
                <caption>
                  <p>Treatment periods for calculating annual forced vital capacity (FVC) decline during CAPACITY and RECAP to assess the association of FVC decline and timing of pirfenidone initiation (aim 2). *Pirfenidone was titrated from 801 mg/d over the first 15 days in RECAP up to the maintenance dose (or maximum tolerated dose if this was lower). CAPACITY = Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes.</p>
                </caption>
                <graphic xlink:href="AnnalsATS.201810-720RL_f1"/>
              </fig>
            </sec>
            <sec disp-level="2">
              <title>Results</title>
              <sec>
                <title>FVC decline by baseline lung function</title>
                <p content-type="flushleft">Overall, 584 individuals who entered RECAP with baseline FVC values were included in this analysis (median age, 69.0 years; male, 71.9%; white, 97.8%; median body mass index [BMI], 28.9 kg/m<sup>2</sup>). At baseline, 28.6%, 52.2%, and 19.2% of individuals had a gender, age, and physiology (GAP) index of I, II, and III, respectively. Mean % predicted FVC and hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (D<sc>l</sc><sub>CO</sub>) at baseline in individuals with available data were 70.9% and 41.1%, respectively (baseline FVC: &lt;50%, <italic>n</italic> = 54; ≥50% to &lt;60%, <italic>n</italic> = 113; ≥60% to &lt;70%, <italic>n</italic> = 136; ≥70% to &lt;80%, <italic>n</italic> = 123; ≥80% to &lt;90%, <italic>n</italic> = 84; ≥90%, <italic>n</italic> = 74).</p>
                <p>For all baseline FVC subgroups, mean declines in % predicted FVC over 180 weeks (2.5–4.3%) and annual rates of FVC decline (101.1–181.0 ml) during RECAP were similar (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
                <fig id="fig2" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Rate of lung function decline over 180 weeks by baseline % predicted forced vital capacity (FVC) category in RECAP.</p>
                  </caption>
                  <graphic xlink:href="AnnalsATS.201810-720RL_f2"/>
                </fig>
              </sec>
              <sec>
                <title>FVC decline and timing of pirfenidone initiation</title>
                <p>Overall, 485 CAPACITY participants (<italic>n</italic> = 236, 2,403 mg/d pirfenidone; <italic>n</italic> = 249, placebo) were enrolled in RECAP and had FVC value(s) recorded in the transition period. Demographics were similar between treatment groups (CAPACITY) and previous treatment groups (RECAP) (median age, 67.0–69.0 yr; male, 69.9–73.5%; white, 97.5–97.7%; median BMI, 29.0–30.0 kg/m<sup>2</sup>). Median % predicted FVC and D<sc>l</sc><sub>CO</sub> at baseline were similar between pirfenidone and placebo groups in CAPACITY (FVC: 73.7% and 72.1%, respectively; D<sc>l</sc><sub>CO</sub>: 45.6% and 45.4%, respectively), and previous pirfenidone and placebo groups in RECAP (FVC: 69.8% and 69.4%, respectively; D<sc>l</sc><sub>CO</sub>: 40.4% and 40.1%, respectively).</p>
                <p>During CAPACITY, annual rate of FVC decline was 142.0 ml and 182.3 ml (–40.3 ml difference) in pirfenidone and placebo groups, respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>). During RECAP, annual rate of FVC decline for previous pirfenidone and placebo groups, respectively, was 155.2 and 151.9 ml (3.3 ml difference) in the transition period and 145.3 and 140.9 ml (4.4 ml difference) after Week 120.</p>
                <fig id="fig3" orientation="portrait" position="float">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Annual rate of lung function decline in CAPACITY and RECAP by treatment group during CAPACITY. *Annual rates of forced vital capacity (FVC) decline during RECAP were calculated on the basis of all available RECAP FVC values, but only presented up to Week 220. CAPACITY = Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes. Adapted by permission from Reference <xref rid="bib12" ref-type="bibr">12</xref>.</p>
                  </caption>
                  <graphic xlink:href="AnnalsATS.201810-720RL_f3"/>
                </fig>
                <p>FVC decline in the placebo group in CAPACITY Study 006 was attenuated (<xref rid="bib3" ref-type="bibr">3</xref>); therefore, this analysis was stratified based on CAPACITY study of origin. The difference between annual rate of FVC decline in the pirfenidone and placebo groups was larger during Study 004 (155.8 vs. 212.1 ml) than Study 006 (128.6 vs. 151.8 ml). Corresponding rates after CAPACITY were 123.2 versus 123.6 ml (previous Study 004) and 187.1 versus 184.7 ml (previous Study 006) during the transition period, and 138.5 versus 137.7 ml (previous Study 004) and 152.3 versus 144.4 ml (previous Study 006) after Week 120.</p>
              </sec>
            </sec>
            <sec disp-level="2">
              <title>Discussion</title>
              <p content-type="flushleft">These <italic>post hoc</italic> analyses of CAPACITY and RECAP found that long-term pirfenidone treatment had similar efficacy regardless of baseline FVC, and there was no effect of prior treatment on FVC change during RECAP. Importantly, loss of lung function that occurred before pirfenidone initiation was not recovered after initiation in RECAP, confirming that delaying antifibrotic treatment results in increased irreversible FVC loss. The efficacy of pirfenidone in reducing FVC decline was maintained for over 4 years, with little change in annual rate of FVC decline after more than 1 year of treatment in individuals who received pirfenidone during CAPACITY. These results are in line with previous analyses indicating that pirfenidone treatment is beneficial in individuals with IPF, regardless of stage of lung function or time since diagnosis at initiation (<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>).</p>
              <p>These findings are limited by the fact that they represent <italic>post hoc</italic> exploratory analyses, and that RECAP was an open-label extension study with no placebo group. Long-term follow-up might have introduced selection bias toward individuals with more preserved lung function over time, because they were less likely to discontinue treatment during CAPACITY or RECAP. In addition, individuals enrolled in CAPACITY had fewer comorbidities than are observed in unselected populations (<xref rid="bib3" ref-type="bibr">3</xref>); thus, the benefits of initiating pirfenidone in individuals with more comorbidities could not be determined.</p>
              <p>Overall, these results add weight to evidence supporting pirfenidone initiation at diagnosis in individuals with IPF to prevent irreversible loss of lung function.</p>
            </sec>
          </body>
          <back>
            <ack>
              <sec>
                <title>Acknowledgment</title>
                <p>Medical writing support was provided by Rebekah Waters, Ph.D. (CMC Affinity, a division of McCann Health Medical Communications, Ltd., Manchester, UK), funded by F. Hoffmann-La Roche, Ltd.</p>
              </sec>
            </ack>
            <fn-group>
              <fn fn-type="supported-by">
                <p>Supported by F. Hoffmann-La Roche, Ltd. (which was involved in study design, collection, analysis, and interpretation of the data).</p>
              </fn>
              <fn>
                <p><italic>Data Sharing Statement</italic>: qualified researchers may request access to individual patient-level data through the clinical study data request platform (<ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudydatarequest.com">www.clinicalstudydatarequest.com</ext-link>). Further details on Roche’s criteria for eligible studies are available from <ext-link ext-link-type="uri" xlink:href="https://clinicalstudydatarequest.com/study-sponsors/study-sponsors-roche.aspx">https://clinicalstudydatarequest.com/study-sponsors/study-sponsors-roche.aspx</ext-link>. For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see: <ext-link ext-link-type="uri" xlink:href="https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm">https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm</ext-link>.</p>
              </fn>
              <fn>
                <p>Clinical trial registered with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT00662038).</p>
              </fn>
              <fn>
                <p><italic>Author Contributions</italic>: All authors were involved in the interpretation of study results, contributed to the letter from the outset, and read and approved the final draft; all authors vouch for the accuracy of the content included in the final letter.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><underline><bold><ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org/doi/suppl/10.1513/AnnalsATS.201810-720RL/suppl_file/disclosures.pdf">Author disclosures</ext-link></bold></underline> are available with the text of this article at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ley</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Collard</surname>
                      <given-names>HR</given-names>
                    </name>
                    <name>
                      <surname>King</surname>
                      <given-names>TE</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <article-title>Clinical course and prediction of survival in idiopathic pulmonary fibrosis</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2011</year>
                  <volume>183</volume>
                  <fpage>431</fpage>
                  <lpage>440</lpage>
                  <pub-id pub-id-type="pmid">20935110</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Raghu</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Remy-Jardin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Myers</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Richeldi</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ryerson</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Lederer</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society</collab>
                  <article-title>Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2018</year>
                  <volume>198</volume>
                  <fpage>e44</fpage>
                  <lpage>e68</lpage>
                  <pub-id pub-id-type="pmid">30168753</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noble</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Albera</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bradford</surname>
                      <given-names>WZ</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Glassberg</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Kardatzke</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>CAPACITY Study Group</collab>
                  <article-title>Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</article-title>
                  <source>
                    <italic>Lancet</italic>
                  </source>
                  <year>2011</year>
                  <volume>377</volume>
                  <fpage>1760</fpage>
                  <lpage>1769</lpage>
                  <pub-id pub-id-type="pmid">21571362</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>King</surname>
                      <given-names>TE</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Bradford</surname>
                      <given-names>WZ</given-names>
                    </name>
                    <name>
                      <surname>Castro-Bernardini</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fagan</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Glaspole</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Glassberg</surname>
                      <given-names>MK</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>ASCEND Study Group</collab>
                  <article-title>A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2014</year>
                  <volume>370</volume>
                  <fpage>2083</fpage>
                  <lpage>2092</lpage>
                  <pub-id pub-id-type="pmid">24836312</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Albera</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Fagan</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Glassberg</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Gorina</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Lancaster</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function</article-title>
                  <source>
                    <italic>Eur Respir J</italic>
                  </source>
                  <year>2016</year>
                  <volume>48</volume>
                  <fpage>843</fpage>
                  <lpage>851</lpage>
                  <pub-id pub-id-type="pmid">27471208</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richeldi</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Cottin</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>du Bois</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Selman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kimura</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Bailes</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials</article-title>
                  <source>
                    <italic>Respir Med</italic>
                  </source>
                  <year>2016</year>
                  <volume>113</volume>
                  <fpage>74</fpage>
                  <lpage>79</lpage>
                  <pub-id pub-id-type="pmid">26915984</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Inoue</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Richeldi</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Collard</surname>
                      <given-names>HR</given-names>
                    </name>
                    <name>
                      <surname>Tschoepe</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Stowasser</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>2016</year>
                  <volume>193</volume>
                  <fpage>178</fpage>
                  <lpage>185</lpage>
                  <pub-id pub-id-type="pmid">26393389</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maher</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Swigris</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Kreuter</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wijsenbeek</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cassidy</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ireland</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views</article-title>
                  <source>
                    <italic>Respiration</italic>
                  </source>
                  <year>2018</year>
                  <volume>96</volume>
                  <fpage>514</fpage>
                  <lpage>524</lpage>
                  <pub-id pub-id-type="pmid">30114692</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Albera</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Lancaster</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>CY</given-names>
                    </name>
                    <name>
                      <surname>Hormel</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hulter</surname>
                      <given-names>HN</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)</article-title>
                  <source>
                    <italic>Respiration</italic>
                  </source>
                  <year>2017</year>
                  <volume>94</volume>
                  <fpage>408</fpage>
                  <lpage>415</lpage>
                  <pub-id pub-id-type="pmid">28898890</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noble</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Albera</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kirchgaessler</surname>
                      <given-names>KU</given-names>
                    </name>
                    <name>
                      <surname>Gilberg</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Petzinger</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U</given-names>
                    </name>
                  </person-group>
                  <article-title>Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment [abstract]</article-title>
                  <source>
                    <italic>Eur Respir J</italic>
                  </source>
                  <year>2016</year>
                  <volume>48</volume>
                  <issue>Suppl 60</issue>
                  <fpage>OA1809</fpage>
                </mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noble</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Albera</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bradford</surname>
                      <given-names>WZ</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>du Bois</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Fagan</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials</article-title>
                  <source>
                    <italic>Eur Respir J</italic>
                  </source>
                  <year>2016</year>
                  <volume>47</volume>
                  <fpage>243</fpage>
                  <lpage>253</lpage>
                  <pub-id pub-id-type="pmid">26647432</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maher</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Jouneau</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Morrison</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lederer</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Molina-Molina</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kirchgaessler</surname>
                      <given-names>KU</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>M28 Deferring treatment with pirfenidone results in loss of lung function that is not recovered by later treatment initiation [abstract]</article-title>
                  <source>
                    <italic>Thorax</italic>
                  </source>
                  <year>2017</year>
                  <volume>72</volume>
                  <issue>Suppl 3</issue>
                  <fpage>A251.2</fpage>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
